Ketamine News and Research

RSS

Psilocybin reconfigures brain networks, showing potential for lasting therapeutic effects

Researchers found that high-dose psilocybin significantly disrupts brain functional connectivity, particularly in the default mode network, with lasting effects linked to therapeutic benefits.

18 Jul 2024

Google searches reveal growing interest in microdosing amid changing drug policies

Loosening local, state and federal regulations on cannabis and psychedelics has increased Americans' interest in microdosing, according to a study from researchers at the University of California San Diego.

28 Jun 2024

Extended-release ketamine tablets offer new hope for treatment-resistant depression

The BEDROC trial found that extended-release ketamine tablets (R-107) significantly improve depressive symptoms in treatment-resistant depression patients, with the 180 mg dose showing the most efficacy. The treatment was well-tolerated with minimal side effects.

26 Jun 2024

New ketamine slow-release tablet shows promise in treating severe depression

A new tablet form of ketamine has shown promise in treating severe depression, offering a potential alternative to existing clinic-based treatments that can be expensive and lacking in convenience for some patients.

24 Jun 2024

Ketamine tablets offer new hope for treatment-resistant depression

For those suffering from treatment-resistant depression, the anaesthetic drug ketamine offers hope, but it has side effects and can be costly to access – a University of Otago-led clinical trial may change that.

24 Jun 2024

Psychoactive drugs are having a moment. The FDA will soon weigh in.

Lori Tipton is among the growing number of people who say that MDMA, also known as ecstasy, saved their lives.

29 May 2024

Study offers new insights into how ketamine works

A World Health Organization Essential Medicine, ketamine is widely used at varying doses for sedation, pain control, general anesthesia and as a therapy for treatment-resistant depression.

21 May 2024

Research highlights complexity of xylazine and fentanyl combination in overdose cases

Unregulated use of fentanyl and overdose deaths have increased dramatically in recent years, and this trend was made more alarming when authorities found fentanyl laced with the animal tranquilizer xylazine.

16 May 2024

Sleep and anesthesia hinder brain toxin clearance, study reveals

Researchers found that brain clearance is reduced during both sleep and anesthesia, contradicting the belief that these states enhance toxin removal.

14 May 2024

New review explores safer treatment approaches for acute agitation in pregnant patients

A recent review article provides critical insights into the management of acute agitation in reproductive-age females and during pregnancy within the emergency departments (EDs).

7 May 2024

STRONG STAR Consortium awarded $17M for traumatic brain injury and psychological health research

In a recent round of grant awards, the STRONG STAR Consortium based at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) was selected by the U.S. Department of Defense for a total of $17 million in funding to launch eight new research projects focused on traumatic brain injury and psychological health.

29 Apr 2024

New technique tracks drug use through smartphones

A simple and convenient method to collect drug use data from the surface of a smartphone is revealed for the first time in a new study published in De Gruyter's Clinical Chemistry and Laboratory Medicine. By helping clinicians understand what drugs people are taking in certain contexts, the research could protect public health and improve the treatment of patients suspected of overdosing.

23 Apr 2024

Ketamine's rapid impact on depression linked to immune system pathways

Study reveals ketamine's potent anti-inflammatory effects on neurological disorders, showing promise for treating major depressive disorder through modulation of neuroimmune pathways.

15 Apr 2024

Esketamine after childbirth cuts risk of postnatal depression by three-quarters

Low-dose esketamine administered post-labor significantly reduced depressive symptoms in women with prenatal depression within 42 days, despite an increase in short-lived neuropsychiatric side effects.

14 Apr 2024

Low dose esketamine injection after childbirth reduces postpartum depression

A single low dose injection of esketamine given immediately after childbirth reduces major depressive episodes in individuals with depressive symptoms during pregnancy (prenatal depression), finds a clinical trial published by The BMJ today.

12 Apr 2024

Tiam1 inhibition mitigates morphine tolerance and hyperalgesia in mouse model

Morphine and other opioids are vital to treat severe and chronic pain. However, they have two problems -; prolonged use creates morphine tolerance, where ever-increasing doses are needed for the same pain relief, and paradoxically, prolonged use also can create an extreme sensitivity to pain, called hyperalgesia.

9 Apr 2024

Ketamine News and Research

Psilocybin reconfigures brain networks, showing potential for lasting therapeutic effects

Google searches reveal growing interest in microdosing amid changing drug policies

Extended-release ketamine tablets offer new hope for treatment-resistant depression

New ketamine slow-release tablet shows promise in treating severe depression

Ketamine tablets offer new hope for treatment-resistant depression

Psychoactive drugs are having a moment. The FDA will soon weigh in.

Study offers new insights into how ketamine works

Research highlights complexity of xylazine and fentanyl combination in overdose cases

Sleep and anesthesia hinder brain toxin clearance, study reveals

New review explores safer treatment approaches for acute agitation in pregnant patients

STRONG STAR Consortium awarded $17M for traumatic brain injury and psychological health research

New technique tracks drug use through smartphones

Ketamine's rapid impact on depression linked to immune system pathways

Esketamine after childbirth cuts risk of postnatal depression by three-quarters

Low dose esketamine injection after childbirth reduces postpartum depression

Tiam1 inhibition mitigates morphine tolerance and hyperalgesia in mouse model

Study finds racial disparities in chemical sedation rates for psychiatric patients in the EDs

When it comes to ketamine, Meta’s posting policy is no party to decipher

Key brain cells linked to repetitive behaviors in psychiatric diseases

RMIT-led study highlights the urgent need for more drug testing facilities in Australia

E-Cigarettes and Ethanol: A forensic Perspective on Vaping

Understanding Consumer-Consented Data to Optimize Digital Health Programs

The Future is Wearable: Advancing Human Health Through Portable Spectroscopy

Latest News